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Abstract
Background: Nephropathy is serious complication of diabetes. We have previously shown that
level of the proteoglycan syndecan-1 in blood is associated with ultrastructural kidney changes in
young persons with type 1 diabetes. Dysregulation of matrix metalloproteinases (MMPs) and tissue
inhibitors of matrix metalloproteinases (TIMPs) may contribute to the development of
nephropathy. The aim of this study was to investigate if the levels of MMPs in blood samples are
potential markers of early nephropathy in type 1 diabetes.
Methods: Blood samples were collected from type 1 diabetes patients after 11 years of diabetes
(n = 15) and healthy volunteers (n = 12) and stored at ÷80°C until measurement. Levels and
activities of serum MMP-2, MMP-9, TIMP-1 and TIMP- 2 were analyzed and compared to those of
control individuals using ELISA, SDS-PAGE gelatin zymography, and Western blot analysis.
Results: The serum levels of both MMP-9 and MMP-2 were significantly higher in subjects with
type 1 diabetes, compared to controls (p = 0.016 and p = 0.008 respectively). Western blotting
revealed no differences between the two groups in the levels of TIMP-1 or TIMP-2, respectively.
Conclusion: Our MMP analysis of serum from a limited number of patients with type 1 diabetes
suggest that such analysis is potentially useful as markers in studies of people at risk of progression
to chronic kidney disease.
Background
Diabetes mellitus (DM) represents a medical problem
affecting millions of people world wide. Chronic hyperg-
lycaemia, measured clinically as elevated glycosylated
hemoglobin A1c (HbA1c), is the most important factor for
the development and progression of microvascular com-
plications like nephropathy, retinopathy and peripheral
neuropathy in diabetes [1].
In the development of diabetic nephropathy, mesangial
expansion and changes in the matrix of glomerular and
tubular basement membranes are important aspects. The
impact of long term hyperglycaemia on the development
of structural changes (i.e. basement membrane thickening
and mesangial expansion) in the kidney has been shown
in studies of type 1 diabetes [2,3]. These changes can be
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arrested or reversed if the blood glucose level is improved
[4] or normalized [5].
The extracellular matrix (ECM) in the basement mem-
brane of the kidney glomeruli is of particular importance
for the filtration properties. Structural changes in mesang-
ial and basement matrix are related to proteinuria and
hypertension and thus the progression of clinical diabetic
nephropathy and kidney failure. One important class of
molecules found in ECM and on cell surfaces and with
functions in kidney filtration are the proteoglycans (PGs).
We have recently shown that serum concentrations of the
proteoglycan syndecan-1 is higher in subjects with type 1
diabetes and microalbuminuria than in those without
microalbuminuria [6] suggesting that it is a potential
serum marker for kidney changes.
Numerous classes of proteolytic enzymes probably partic-
ipate in ECM degradation, and one class that appears to
play a major role is MMPs [7] and their inhibitors, the
TIMPs. MMPs have been shown to be increased in several
diseases and secretion and activity to be strictly regulated.
Gelatinase A (MMP-2) and gelatinase B (MMP-9) are the
most important MMPs in normal kidneys and are there-
fore assumed to play major roles in basement membrane
homeostasis [8].
Our studies on cultured human endothelial cells have
established that primary human umbilical cord endothe-
lial cells (HUVEC) exposed to hyperglycaemic conditions
reduced secretion of MMP-2. MMP-9 secretion was negli-
gible or very low in these cells, irrespective of treatment
[9]. We have also established that HUVEC decreased the
secretion of PGs including that of syndecan-1 under
hyperglycemic conditions [10].
The aim of this study was to investigate if the activities
and/or levels of MMPs in blood samples are markers of
early nephropathy in type 1 diabetes
Methods
Patients
Blood samples were obtained from subjects with type 1
diabetes and microalbuminuria who participated in a pro-
spective study. The study focused on blood glucose con-
trol and on morphological changes in the glomeruli. The
inclusion criteria in this study were persistent microalbu-
minuria, defined as an AER between 15-200 μg/min in at
least two out of three overnight urine samples taken dur-
ing 1 year. At the time when the blood samples were
obtained the mean duration of diabetes was 11.3 (7-18)
and the mean age was 22 (19-30). The mean age of the
controls was 31 (26-35) years. Details from this study
have been presented [4]. In short, body mass index (BMI)
was below 25 for all except one patient whose BMI was
29.6 (19.7-29.6). Further, only two patients were dyslipi-
demic with cholesterol/HDL cholesterol ratios of 6.9 and
9.5, respectively, mainly due to low HDL-cholesterol lev-
els. The patients were all examined by the same investiga-
tor (HJB). Blood aliquots from 15 patients were taken and
stored at -80°C. Healthy controls without type 1 diabetes
(n = 12), male and female, were recruited from students
and staff within the Department of Nutrition. These sam-
ples were also frozen. The present study focus on samples
from the start of the study when the patients had micro-
albuminuria, but neither clinical nephropathy nor prolif-
erative retinopathy, and all except one patient had blood
pressure < 140/90 mmHg at the start of the study. All
available samples were used. Samples were not subjected
to thawing and freezing between sampling and analyses,
to avoid loss of activity. All subjects in this study gave
informed consent and the protocol was approved by the
Regional Ethical Committee for Health Region South in
Norway and conformed to the Helsinki Declaration.
Zymography
SDS-PAGE gelatin-substrate zymography was used to ana-
lyze for gelatinases and urokinase. To detect gelatinases,
SDS-PAGE gels contained 0.1% gelatin (Collagen type B
from bovine skin, Sigma-Aldrich, Oslo, Norway). Positive
control for proMMP-9 monomer (92 kDa) and
homodimer (225 kDa) was conditioned serum-free
medium from THP-1 cells. Positive control for active (62
kDa) and pro (72 kDa) forms of MMP-2 was conditioned
serum-free medium from an osteosarcoma cell line.
The serum samples were mixed with sample buffer and
loaded on 7.5% gels containing 0.1% gelatin. Protein con-
centrations of the samples were determined using the BC
assay from Uptima (Interchim, Monttucon, France). After
electrophoresis, the gels were incubated in 2.5% Triton X-
100 to wash out SDS and then in assay buffer (0.05 M
Tris-buffer pH 8.0 with 0.2 M NaCl, 0.005 M CaCl2 and
0.02% wt/vol Brij-35) overnight at 37°C to allow possible
enzymes in the samples to degrade the gelatin matrix. In
some experiments, wash and assay buffers contained the
metalloproteinase inhibitor EDTA (10 mM).
To visualize gelatin lysis, gels were then stained with
Coomassie blue and destained with ethanol: acetic acid:
water (15: 5: 30). Areas containing gelatinolytic activity
appeared as clear white zones on the blue-stained back-
ground. To obtain quantitative information the areas con-
taining gelatinolytic activity were analysed in a
Phosphoimager (Amersham Biosciences, UK).
ELISA assay
The concentrations of MMP-2 and MMP-9 were deter-
mined in blood samples using ELISA kits from AmershamBMC Clinical Pathology 2009, 9:7 http://www.biomedcentral.com/1472-6890/9/7
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Biosciences, where the use of serum for these analyses was
recommended.
Western Blotting
Samples were mixed with Laemmli sample buffer, heated
and electrophoresed in 10% (to detect MMP-9 and MMP-
2) or 15% (to detect TIMP-1 and TIMP-2) SDS-PAGE gels
(Bio-Rad, Hercules, CA, USA) and subjected to Western
blotting as previously described [9].
Statistical methods
Because variables were not normally distributed, nonpar-
ametric statistical analyses (Mann-Whitney tests) were
used. Data are presented as means ± SEM or median val-
ues (interquartile intervals) as indicated. Comparison
between groups of data was done by using box-plots. Sta-
tistical significance was defined as p < 0.05. All analyses
were performed with SPSS for Windows version 16.
Results
Blood samples from controls and subjects with type 1 dia-
betes were analyzed by SDS-PAGE gelatin zymography. In
all blood samples, bands with gelatinase activities were
detected at positions that corresponded with monomeric
(92 kDa) and homodimeric (225 kDa) forms of proMMP-
9, and proMMP-2 (72 kDa) in the standards (Figure 1A).
These gelatinases did not appear when gels were washed
and incubated in the presence of 10 mM EDTA (Figure
1B), which shows that they are metalloproteinases. The
amounts of the 72 kDa gelatinase were consistently lower
than those of the 92 kDa gelatinase in all experiments. To
further identify the bands at 72 and 92 kDa, Western blot
analysis was performed on reduced blood samples using
antibodies against MMP-2 and MMP-9. This revealed that
the 72 kDa band is proMMP-2 and the 92 kDa band is
proMMP-9 (Figure 2A). During analysis we observed that
almost all samples contained gelatinase activity in the top
region of the gel. This most likely represents dimeric
MMP-9, but has not been studied further.
We further determined the concentrations of MMP-2 and
MMP-9 in samples from subjects with type 1 diabetes and
controls using ELISA. As can be seen in Figure 3A the
serum levels of MMP-9 were significantly higher in
patients with diabetes (median: 0.0170 ng/ml; interquar-
tile range, 0.0230 ng/ml) compared to healthy controls
(median = 0.0055 ng/ml; interquartile range, 0.0145 ng/
ml; p = 0.016). The levels of MMP-2 (Figure 3B) were also
significantly higher in the diabetes group (median:
0.17250 ng/ml; interquartile range, 0.0735 ng/ml) com-
pared to healthy controls (median = 0.13850 ng/ml; inter-
quartile range, 0.0640 ng/ml; p = 0.008).
To investigate if TIMP concentrations differed in the
obtained control and diabetes samples we performed
Western blotting with antibodies against TIMP-1 and
TIMP-2. Samples from both patients and controls con-
tained detectable levels of TIMP-1 and TIMP-2. However,
no apparent differences in the respective TIMPs could be
observed in blood samples from the two different groups
tested (Figure 2B).
Discussion
In the present study serum from controls and from sub-
jects with type 1 diabetes have been analysed for content
of MMPs. The results presented show that the concentra-
tions of MMP-9 and MMP-2 in serum were elevated in the
patients. The results presented are from a limited number
SDS-PAGE zymography of serum samples Figure 1
SDS-PAGE zymography of serum samples. Three 
serum samples taken from controls and three samples from 
subjects with type 1 diabetes were subjected to gel electro-
phoresis to detect possible gelatinolytic activities, in the 
absence (Panel A) and presence of 10 m EDTA (Panel B). The 
migration position of the 72 kDa (proMMP-2) and 92 kDa 
(proMMP-9) and dimeric proMMP-9 (225 kDa) standards are 
shown at the right side of panel A.
Controls                  Patients
1       2      3              1      2     3
B
Controls                   Patients
1      2      3              1      2      3
225 kDa
92 kDa
72 kDa
ABMC Clinical Pathology 2009, 9:7 http://www.biomedcentral.com/1472-6890/9/7
Page 4 of 5
(page number not for citation purposes)
of patients with type 1 diabetes and conclusions should
therefore be drawn with caution.
Results published on the use of MMPs as markers in rela-
tion to diabetic complications are somewhat conflicting.
Increased MMP-2 levels, in particular in urine, have been
related to increased risk of nephropathy [11]. Also, the use
of MMP-9 as a surrogate marker for retinopathy has been
suggested [12]. In addition, increased circulatory MMP-9,
as well as MMP-2, has been reported in older subjects with
type 1 diabetes [13]. In a study on children and adoles-
cents, increased MMP-2 levels were suggested to be a
marker of microangiopathy [14]. However, MMP-2 levels
in plasma from subjects with diabetes type 1 and normal
renal function did not differ from controls. Furthermore,
MMP-9 was detected in patient plasma, but not in con-
trols [15]. TIMP-1 concentrations were elevated in the dia-
betes group, but this change did not seem to be linked to
vascular disease [15]. However, these studies were per-
formed on plasma, whereas our studies were done on
serum samples. These results referred to on MMP-2, but
not those on MMP-9 and TIMP-1, support our findings.
Changes in the extracellular matrix are evident in the dia-
betic kidney [2,3]. It has been demonstrated that the
thickness of the basement membrane is increased in sub-
jects with type 1 diabetes, and that such changes can be
arrested by improved blood glucose control [4]. The
changes in the ECM of the kidney (i.e. glomeruli and
tubuli) contribute to the development of albuminuria,
and at the end kidney failure. The question is if the blood
concentrations of MMPs, TIMPs and PGs are potential
markers for such changes. Sensitive markers can increase
our understanding of the process leading to kidney failure
and possibly detect subjects with high risk of progression
to chronic kidney disease which again would facilitate
early treatment.
Western blotting of serum samples Figure 2
Western blotting of serum samples. Samples from sub-
jects with type 1 diabetes and control samples were sub-
jected to Western blotting using antibodies against MMP-2, 
MMP-9 (Panel A), and TIMP-1 and TIMP-2 (Panel B). Stand-
ards with MMP-2, MMP-9, TIMP-1 and TIMP-2 were sub-
jected to the same procedures.
MMP-9
MMP-2
A
Controls                   Patients
1      2     3     1     2    3     4    5     6
B  Controls             Patients
1     2     3     1    2    3      4    5     6
TIMP 1
TIMP 2
Box plot analysis based on ELISA analyses Figure 3
Box plot analysis based on ELISA analyses. The con-
centrations of MMP-9 (Panel A) and MMP-2 (Panel B) were 
determined in 12 control samples and 15 samples from per-
sons with diabetes and these data were used for the box 
plot. In panel A there are two outliers in the control group. * 
p < 0.05.
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In a previous study syndecan-1 was shown to be elevated
in blood samples from the same subjects studied here,
who all had microalbuminuria [6]. We did not find any
correlation between elevated syndecan-1 concentrations
and neither MMP-9 nor MMP-2 levels in these samples
(unpublished observation). Although our results here
show elevated levels of MMP-9 and MMP-2 it is tempting
to speculate that syndecan-1 levels in blood may be a bet-
ter marker for kidney changes. In future studies it would
be of interest to compare MMP levels with syndecan-1 lev-
els in larger cohorts of persons with type 1 or type 2, com-
paring those with and without microalbuminuria.
Conclusion
Our MMP analysis of serum from a limited number of
patients with type 1 diabetes suggest that such analysis is
potentially useful as markers in studies of people at risk of
progression to chronic kidney disease.
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